Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Selected Grants and Awards

Publications

WOOLAS, R, XU, FJ, DALY, L, SOPER, JT, BERCHUCK, A, RODRIGUEZ, G, CLARKEPEARSON, DL, BOYER, CM, and BAST, RC. "SCREENING STRATEGIES FOR OVARIAN-CANCER." DIAGNOSTIC ONCOLOGY 3, no. 6 (1993): 287-293.

Scholars@Duke

Rodriguez, GC, Boente, MP, Berchuck, A, Whitaker, RS, O Briant, KC, Xu, F, and Bast, RC. "The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines." American Journal of Obstetrics and Gynecology 168, no. 1 (January 1, 1993): 228-232.

Full Text

Rodríguez, GC, Boente, MP, Berchuck, A, Whitaker, RS, O'Briant, KC, Xu, F, and Bast, RC. "The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines." Am J Obstet Gynecol 168, no. 1 Pt 1 (January 1993): 228-232.

Scholars@Duke

RODRIGUEZ, GC, BOENTE, MP, BERCHUCK, A, WHITAKER, RS, OBRIANT, KC, XU, FJ, and BAST, RC. "THE EFFECT OF ANTIBODIES AND IMMUNOTOXINS REACTIVE WITH HER-2/NEU ON GROWTH OF OVARIAN AND BREAST-CANCER CELL-LINES." AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 168, no. 1 (January 1993): 228-232.

Full Text

Jacobs, IJ, Kohler, MF, Wiseman, RW, Marks, JR, Whitaker, R, Kerns, BA, Humphrey, P, Berchuck, A, Ponder, BA, and Bast, RC. "Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation." J Natl Cancer Inst 84, no. 23 (December 2, 1992): 1793-1798.

Scholars@Duke

Soper, JT, Johnson, P, Johnson, V, Berchuck, A, and Clarke-Pearson, DL. "Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma." Obstet Gynecol 80, no. 6 (December 1992): 949-953.

Scholars@Duke

Soisson, AP, Soper, JT, Berchuck, A, Dodge, R, and Clarke-Pearson, D. "Radical hysterectomy in obese women." Obstet Gynecol 80, no. 6 (December 1992): 940-943.

Scholars@Duke

Boente, MP, Berchuck, A, Rodriguez, GC, Davidoff, A, Whitaker, R, Xu, FJ, Marks, J, Clarke-Pearson, DL, and Bast, RC. "The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells." Am J Obstet Gynecol 167, no. 6 (December 1992): 1877-1882.

Scholars@Duke

Wiener, JR, Berchuck, A, and Bast, RC. "Biology and therapy with biologic agents in gynecologic cancer." Curr Opin Oncol 4, no. 5 (October 1992): 946-954. (Review)

Scholars@Duke

Olt, G, Berchuck, A, Soisson, AP, Boyer, CM, and Bast, RC. "Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer." Cancer 70, no. 8 (October 1992): 2137-2142.

Full Text

Pages